HEMOPHILIA A IS A PIECE OF THEM.
NOT ALL OF THEM .
ADYNOVATE ® has a simple , twice-weekly dosing schedule on the same 2 days every week that can help personalize treatment , so your patients have more time to spend doing the other things that also make them who they are . 1 , 2
* In clinical trials , ADYNOVATE demonstrated the ability to help patients prevent bleeding episodes using a prophylaxis regimen .
AdynovateRealLife . com / HCP
Print-only content
DETAILED IMPORTANT RISK INFORMATION
CONTRAINDICATIONS Prior anaphylactic reaction to ADYNOVATE , to the parent molecule ( ADVATE ® [ Antihemophilic Factor ( Recombinant )]), mouse or hamster protein , or excipients of ADYNOVATE ( e . g . Tris , mannitol , trehalose , glutathione , and / or polysorbate 80 ).
WARNINGS & PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions are possible with ADYNOVATE . Allergictype hypersensitivity reactions , including anaphylaxis , have been reported with other recombinant antihemophilic factor VIII products , including the parent molecule , ADVATE . Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema , chest tightness , dyspnea , wheezing , urticaria , and pruritus . Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur .
Neutralizing Antibodies Formation of neutralizing antibodies ( inhibitors ) to factor VIII can occur following administration of ADYNOVATE . Monitor patients regularly for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests . Perform an assay that measures factor VIII inhibitor concentration if the plasma factor VIII level fails to increase as expected , or if bleeding is not controlled with expected dose .
ADVERSE REACTIONS The most common adverse reactions reported in clinical studies were headache , diarrhea , rash , nausea , dizziness and urticaria .
Please see the following page for the Brief Summary of the ADYNOVATE Full Prescribing Information . For Full Prescribing Information , visit www . adynovatepro . com .
REFERENCES : 1 . Valentino LA . Considerations in individualizing prophylaxis in patients with haemophilia A . Haemophilia . 2014 ; 20 ( 5 ): 607-615 . 2 . ADYNOVATE Prescribing Information .
© 2021 Takeda Pharmaceuticals U . S . A ., Inc . 300 Shire Way , Lexington , MA 02421 . 1-877-TAKEDA-7 . All rights reserved . TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited . ADVATE and ADYNOVATE are registered trademarks of Baxalta Incorporated , a Takeda company . US-ADY-0321v2.0 07 / 21